Exosome (CreepCrohn)
Advanced therapy based on the therapeutic action of stem cell-derived extracellular vesicles for Crohn's disease.
Are you interested?Need
Despite the current therapeutic arsenal for treating Crohn’s disease (CD), which includes biologic treatments, more than 50% of patients will require at least one surgical intervention within 10 years of diagnosis,CD is an immune-mediated disease characterized by transmural lesions that facilitate contact between antigens, metabolites and the microbiota inhabiting the intestinal lumen and mesenteric adipose tissue (MAT). Consequently, the TAM undergoes hyperplasia and adopts a pro-inflammatory state, colloquially known as creeping fat (CrF), leading to a decrease in its protective capabilities. This, in turn, triggers CrF to instigate exacerbated inflammatory responses, perpetuating a deleterious inflammatory cycle. Disease severity has been correlated with the presence of CrF.
Solution
Advanced therapy with extracellular vesicles (EVs) of adipose tissue mesenchymal stem cells (AT-MSCs) encapsulated in hydrogel, lyophilized and injectable by laparoscopy in the target tissue for the treatment of Crohn’s disease (CD). Therapeutic product validated in different cell types and in ex vivo models (CrF and mucosal biopsies) demonstrating a 200-fold reduction of inflammatory cytokines.
Objective
Main objective: Development of an etiological therapy, by means of in situ administration by laparoscopy and sustained release of the therapeutic product, with the aim of reestablishing eubiosis and avoiding intestinal resection surgeries typical of patients with Crohn’s disease.